Menarini

"Paediatric network against ill-treatment of minors" has been launched and supported by the pharmaceutical company, Menarini, together with :it:Telefono Azzurro, the Italian Federation of Paediatricians, and the Association of Italian Paediatric Hospitals, has grown beyond Italian borders.{{Citation needed|date=January 2021}}

The project originated in Italy and is the first of its kind in the world. It was launched in May 2016 in the city of Florence and is supported by Menarini with an investment of one million euro. It foresees the creation of a network of 15,000 paediatricians and general practitioners deployed over the entire Italian territory who act as 'sentinels' in the fight against child abuse. These physicians, who have been 'trained' on the skills needed to recognise the unexpressed 'sentinel' warning signs of child abuse, shall in turn become reference people for their colleagues on a local level, providing qualified information and advice. This project is for the creation of an anti-abuse network.{{Cite web|date=2016-05-12|title=15,000 doctors against child abuse - English|url=http://www.ansa.it/english/news/general_news/2016/05/12/15000-doctors-against-child-abuse_10d590d0-06eb-4507-b609-13be0d43d06f.html|access-date=2021-01-12|website=ANSA.it|language=en}}

On 18 October 2016 the project was presented in Tirana to more than 500 paediatricians, not only from the Balkans but also from other countries such as Romania, Switzerland, Turkey and others.{{Cite web|title=Press Release|url=https://www.menarini.com/Home/Menarini-News/News/News-details/ArticleId/2321/Press-Release|access-date=2021-01-12|website=Menarini Group|language=en-US}}{{Self-published inline|date=January 2021}}

The Menarini pharmaceutical group is committed to the recovery of several social housing owned by the municipality of Florence. So far the apartments recovered are 20 and have been assigned to families of small and medium size. The surfaces of the delivered housing range from 50 to 70 square metres each. The first agreement between the Menarini Group and the City of Florence was presented on 16 July 2013 by the mayor of Florence, Matteo Renzi and Lucia Aleotti, President of the Menarini pharmaceutical group.[http://press.comune.fi.it/hcm/hcm5353-10_2_73-Dieci+alloggi+Erp+ristrutturati+e+assegnati+grazie.html?cm_id_details=67903&id_padre=4471 Dieci alloggi Erp ristrutturati e assegnati grazie a Menarini]

On 18 January 2014 the Menarini Group has delivered the first three of 10 apartments, located in Via Rocca Tedalda, in the south side of Florence.[http://www.comune.fi.it/export/sites/retecivica/comune_firenze/ultime_notizie/e0403.html Consegnati i primi tre alloggi di edilizia popolare ristrutturati grazie a Menarini] {{webarchive|url=https://web.archive.org/web/20161220210620/http://www.comune.fi.it/export/sites/retecivica/comune_firenze/ultime_notizie/e0403.html|date=2016-12-20}}

On 27 March 2014, the keys of the last 7 houses of the first edition of the project were delivered.{{Cite web|last=Nazione|first=La|title=Case popolari: consegnati alloggi a sette famiglie|url=https://www.lanazione.it/firenze/cronaca/2014/03/27/1045201-case-popolari-nardella-menarini.shtml|access-date=2021-01-12|website=La Nazione|date=27 March 2014 |language=it}}

On 12 December 2014 it was announced the second edition of the project of social housing redevelopment in Palazzo Vecchio by Mayor Dario Nardella, the President and the vice-chairman of the pharmaceutical group Menarini Lucia and Alberto Giovanni Aleotti.[http://press.comune.fi.it/hcm/hcm5353-10_2_1-Erp%2C+Menarini+ristruttura+altri+10+alloggi.+Potran.html?cm_id_details=72795&id_padre=4471 Erp, Menarini ristruttura altri 10 alloggi. Potranno essere assegnati già nella primavera del 2015]

On 21 April 2015, 10 apartments renovated from Menarini were delivered to 10 needy families in the city.[http://press.comune.fi.it/hcm/hcm5353-10_2_1-Consegnati+nel+Quartiere+5+dieci+alloggi+Erp+ad+al.html?cm_id_details=74319&id_padre=4471 Consegnati nel Quartiere 5 dieci alloggi Erp ad altrettante famiglie bisognose]

On 30 November 2015 it was announced the third edition of the project.[http://press.comune.fi.it/hcm/hcm5353-10_2_1-Edilizia+residenziale+pubblica%2C+Menarini+ristruttu.html?cm_id_details=76890&id_padre=4471 Edilizia residenziale pubblica, Menarini ristruttura altri 10 alloggi popolari nei quartieri 4 e 5]

On 17 June 2016 the Menarini Group and the City of Florence have handed over the keys of 10 renovated houses to those families included in the social rankings of the city.[http://press.comune.fi.it/hcm/hcm5353-10_2_1-Consegnati+altri+10+alloggi+ristrutturati+da+Menar.html?cm_id_details=79597&id_padre=4471 Consegnati altri 10 alloggi ristrutturati da Menarini]

In March 2018, the company announced the new board of directors of the company which for the first time saw an external manager, Eric Cornut, fill the role of president.{{Cite web |date=2018-03-22 |title=Menarini, la presidenza passa a un membro esterno alla famiglia Aleotti: Eric Cornut |url=https://www.aboutpharma.com/aziende/menarini-la-presidenza-passa-un-membro-esterno-alla-famiglia-aleotti/ |access-date=2022-05-26 |website=AboutPharma |language=it-IT}} Cornut, a Swiss from Basel with a master's degree in California, a life in Novartis and for two years, until April 2017, in charge of the general management of Epfia, the European Federation of Pharmaceutical Industries.{{Cite web |date=2018-04-09 |title=Eric Cornut: "Così farò entrare Menarini nell'Olimpo di Big Pharma" |url=https://www.repubblica.it/economia/affari-e-finanza/2018/04/09/news/eric_cornut_cos_far_entrare_menarini_nellolimpo_di_big_pharma-193375524/ |access-date=2022-05-26 |website=la Repubblica |language=it}} On 12 September 2019, the Board of Directors appointed Elcin Barker Ergun as the company's CEO.{{Cite web |date=2019-09-12 |title=Menarini, Elcin Barker Ergun nominata CEO |url=https://www.ilmessaggero.it/economia/news/menarini_elcin_barker_ergun_nominata_ceo-4729789.html |access-date=2022-05-26 |website=www.ilmessaggero.it |language=it}}

The Menarini Group continued its operations in Russia despite the international sanctions imposed following Russia's invasion of Ukraine.{{Cite web |title=Menarini Group - Leave Russia |url=https://leave-russia.org/menarini-group |access-date=2024-12-26 |website=Leave Russia}} The company faced criticism from organizations promoting corporate accountability and ethical practices in regions affected by geopolitical conflicts.{{Cite web |title=Corporate Responses to Sanctions Against Russia |url=https://leave-russia.org/menarini-group |access-date=2024-12-26 |website=Leave Russia}}

• Dexketoprofen
• Ibodutant
• Berlin Chemie

{{div col|colwidth=30em}}

• {{cite journal|title=Handling with missing data in clinical trials for time-to-event variables|journal=PharmaSUG|date=2014|volume=SP02|pages=1–9|url=http://www.pharmasug.org/proceedings/2014/SP/PharmaSUG-2014-SP02.pdf|access-date=2016-11-07|language=en}}
• {{cite journal|title=Ranolazine Reduces The Late Recurrences Of Atrial Fibrillation. An Exploratory Analysis Of The Raffaello Study|journal=Treatment of Arrhythmias: Pharmacological-atrial Fibrillation|date=November 2014|volume=130|url=http://circ.ahajournals.org/content/130/Suppl_2/A16181|access-date=2016-11-07|language=en}}
• {{cite journal|title=MEN1112, a Novel Humanized De-Fucosylated Monoclonal Antibody with High Affinity and Specificity for Bst1/CD157 Antigen and Enhanced CD16 Binding|journal=56th ASH Annual Meeting and Exposition, S. Francisco (CA)|date=December 2014|volume=124|page=3607|url=http://www.bloodjournal.org/content/124/21/3607|access-date=2016-11-07|language=en}}
• {{cite journal|title=Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen|journal=56th ASH Annual Meeting and Exposition, S. Francisco (CA)|date=December 2014|volume=124|page=2235|url=http://www.bloodjournal.org/content/124/21/2235|access-date=2016-11-07|language=en}}
• {{cite journal|title=Prophylaxis with Febuxostat in comparison to Allopurinol reduces exposure to uric acid in patients at intermediate to high risk of tumor lysis syndrome: results of the Florence study|journal=19th Congress of the European Hematology Association, Milano|date=June 2014|url=https://www.researchgate.net/publication/275464714|access-date=2016-11-07|language=en}}
• {{cite journal|title=Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study|journal=Blood|date=December 2014|volume=124|page=5979|doi=10.1182/blood.V124.21.5979.5979|url=https://www.researchgate.net/publication/292967973|access-date=2016-11-07|language=en|last1=Baldini|first1=Simone|last2=Rossi|first2=Cristina|last3=Spina|first3=Michele|last4=Federico|first4=Massimo|last5=Nagy|first5=Zsolt|last6=Jordan|first6=Karin|last7=Aurer|first7=Igor|last8=Ribera|first8=Josep-Maria|last9=Borsaru|first9=Gabriela|last10=Glushko|first10=Nataliia|last11=Grosicki|first11=Sebastian|last12=Pristupa|first12=Alexander|last13=Bosi|first13=Alberto|last14=Rego|first14=Eduardo M.|last15=Nizzardo|first15=Andrea|last16=Scartoni|first16=Simona|last17=Scordari|first17=Alessandra|last18=Matera|first18=Mariagiuseppa|last19=Maggi|first19=Carlo Alberto|last20=Capriati|first20=Angela|last21=Simonelli|first21=Cecilia|issue=21|doi-access=free}}
• {{cite journal|title=A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study|journal=Clin Oncol|date=June 2014|volume=32|url=https://www.researchgate.net/publication/280298390|access-date=2016-11-07|language=en}}
• {{cite journal|title=Sa1080 Concordance Among Outcome Variables Assessing the Response to Treatment With Ibodutant in Irritable Bowel Syndrome With Diarrhea (IBS-D; the IRIS-2 Study)|journal=Gastroenterology|date=May 2014|volume=146|issue=5|page=194|url=https://www.researchgate.net/publication/288326937|access-date=2016-11-07|language=en|doi=10.1016/s0016-5085(14)60684-3|last1=Tack|first1=Jan F.|last2=Capriati|first2=Angela|last3=Schumacher|first3=Kai|last4=Ligas|first4=Franca|last5=Ott|first5=Kerstin|last6=Tonini|first6=Giulia|last7=Scartoni|first7=Simona|last8=Otranto|first8=Isabella|last9=Nuti|first9=Alessandra|last10=Maggi|first10=Carlo Alberto|doi-access=free}}
• {{cite journal|title=Blood pressure control is similar in treated hypertensive patients with optimal or with high-normal albuminuria|journal=American Journal of Hypertension|date=March 2014|volume=27|issue=9|pages=1185–1190|pmid=24646879|url=https://www.researchgate.net/publication/261476090|access-date=2016-11-07|language=en|doi=10.1093/ajh/hpu039 | last1 = Oliveras | first1 = A | last2 = Armario | first2 = P | last3 = Lucas | first3 = S | last4 = de la Sierra | first4 = A|doi-access=free}}
• {{cite journal|title=Comparative Performance Assessment of Point-of-Care Testing Devices for Measuring Glucose and Ketones at the Patient Bedside|journal=Journal of Diabetes Science and Technology|date=December 2014|volume=9|issue=2|pmid=25519295|language=en|doi=10.1177/1932296814563351|pmc=4604596|pages=268–77 | last1 = Ceriotti | first1 = F | last2 = Kaczmarek | first2 = E | last3 = Guerra | first3 = E | last4 = Mastrantonio | first4 = F | last5 = Lucarelli | first5 = F | last6 = Valgimigli | first6 = F | last7 = Mosca | first7 = A}}
• {{cite journal|title=EHMTI-0052. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura|journal=The Journal of Headache and Pain|date=May 2014|volume=35|issue=1|pages=107–113|pmid=24867846|language=en|doi=10.1007/s10072-014-1751-3|pmc=4035546 | last1 = Allais | first1 = G | last2 = Tullo | first2 = V | last3 = Cortelli | first3 = P | last4 = Barbanti | first4 = P | last5 = Valguarnera | first5 = F | last6 = Sette | first6 = G | last7 = D'Onofrio | first7 = F | last8 = Curone | first8 = M | last9 = Zava | first9 = D | last10 = Pezzola | first10 = D | last11 = Reggiardo | first11 = G | last12 = Omboni | first12 = S | last13 = Frediani | first13 = F | last14 = Bussone | first14 = G | last15 = Benedetto | first15 = C}}
• {{cite journal|title=Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition|journal=Cardiovascular Research|date=February 2014|volume=102|issue=1|pages=138–147|pmid=24501330|url=https://www.researchgate.net/publication/260118129|access-date=2016-11-07|language=en|doi=10.1093/cvr/cvu026 | last1 = Bucci | first1 = M | last2 = Vellecco | first2 = V | last3 = Cantalupo | first3 = A | last4 = Brancaleone | first4 = V | last5 = Zhou | first5 = Z | last6 = Evangelista | first6 = S | last7 = Calderone | first7 = V | last8 = Papapetropoulos | first8 = A | last9 = Cirino | first9 = G| doi-access = free }}
• {{cite journal|title=Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis|journal=Arteriosclerosis, Thrombosis, and Vascular Biology|date=February 2014|volume=34|issue=4|pages=820–829|pmid=24558107|url=https://www.researchgate.net/publication/260372139|access-date=2016-11-07|language=en|doi=10.1161/atvbaha.114.303290 | last1 = Momi | first1 = S | last2 = Caracchini | first2 = R | last3 = Falcinelli | first3 = E | last4 = Evangelista | first4 = S | last5 = Gresele | first5 = P|doi-access=free}}
• {{cite journal|title=Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study|journal=The Journal of Pain|date=January 2014|volume=333|issue=4|pages=388–394|pmid=24412801|url=https://www.researchgate.net/publication/259698737|access-date=2016-11-07|language=en|doi=10.1016/j.jpain.2013.12.006 | last1 = Mainardi | first1 = F | last2 = Maggioni | first2 = F | last3 = Pezzola | first3 = D | last4 = Zava | first4 = D | last5 = Zanchin | first5 = G|doi-access=free}}
• {{cite journal|title=Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients|journal=Advances in Therapy|date=January 2014|volume=31|issue=2|pages=217–233|pmid=24415271|language=en|doi=10.1007/s12325-013-0090-8|pmc=3930838 | last1 = Agabiti-Rosei | first1 = E | last2 = Manolis | first2 = A | last3 = Zava | first3 = D | last4 = Omboni | first4 = S}}
• {{cite journal|title=Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study|journal=Cephalalgia|date=December 2013|volume=34|issue=6|pages=434–445|pmid=24363238|url=https://www.researchgate.net/publication/259449446|access-date=2016-11-07|language=en|doi=10.1177/0333102413515342 | last1 = Tullo | first1 = V | last2 = Valguarnera | first2 = F | last3 = Barbanti | first3 = P | last4 = Cortelli | first4 = P | last5 = Sette | first5 = G | last6 = Allais | first6 = G | last7 = d'Onofrio | first7 = F | last8 = Curone | first8 = M | last9 = Zava | first9 = D | last10 = Pezzola | first10 = D | last11 = Benedetto | first11 = C | last12 = Frediani | first12 = F | last13 = Bussone | first13 = G| doi-access = free }}
• {{cite journal|title=Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies|journal=Neurological Sciences|date=May 2014|volume=35|issue=1|pages=115–119|pmid=24867847|url=https://www.researchgate.net/publication/262681049|access-date=2016-11-07|language=en|doi=10.1007/s10072-014-1752-2 | last1 = Saracco | first1 = MG | last2 = Allais | first2 = G | last3 = Tullo | first3 = V | last4 = Zava | first4 = D | last5 = Pezzola | first5 = D | last6 = Reggiardo | first6 = G | last7 = Omboni | first7 = S | last8 = Benedetto | first8 = C | last9 = Bussone | first9 = G | last10 = Aguggia | first10 = M|s2cid=20224729}}
• {{cite journal|title=Inner and outer portions of colonic circular muscle: ultrastructural and immunohistochemical changes in rat chronically treated with otilonium bromide|date=January 2015|pmid=25122192|language=en|doi=10.1371/journal.pone.0103237|volume=9|issue=8|pmc=4133200|journal=PLOS ONE|page=e103237 | last1 = Traini | first1 = C | last2 = Faussone-Pellegrini | first2 = MS | last3 = Evangelista | first3 = S | last4 = Mazzaferro | first4 = K | last5 = Cipriani | first5 = G | last6 = Santicioli | first6 = P | last7 = Vannucchi | first7 = MG|doi-access=free}}
• {{cite journal|title=Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation|journal=PLOS ONE|date=January 2014|volume=9|issue=1|pmid=24392129|language=en|doi=10.1371/journal.pone.0084358|pmc=3879294|page=e84358 | last1 = Terzuoli | first1 = E | last2 = Meini | first2 = S | last3 = Cucchi | first3 = P | last4 = Catalani | first4 = C | last5 = Cialdai | first5 = C | last6 = Maggi | first6 = CA | last7 = Giachetti | first7 = A | last8 = Ziche | first8 = M | last9 = Donnini | first9 = S|bibcode=2014PLoSO...984358T|doi-access=free}}

{{div col end}}

{{Reflist}}

• {{Official website|http://www.menarini.com/ }}

{{Authority control}}

Category:Pharmaceutical companies of Italy

Category:Companies based in Florence

Category:Pharmaceutical companies established in 1886

Category:Italian companies established in 1886

Category:Italian brands

Category:Multinational companies headquartered in Italy